Mobile Intervention - Physical Activity in Cancer Treatment

Status Terminated

Clinical Trial Summary

Aim 1. Determine the feasibility and acceptability of the proposed mobile technology intervention to increase physical activity patients receiving treatment for renal cell carcinoma. Aim 2. Evaluate the effect of the proposed intervention components (affective framing, intention planning, and goal-setting) on changes in physical activity.

Clinical Trial Description

Recent analyses have indicated that physical activity reduces mortality risk among patients with RCC.1. Physical activity also provides additional benefits for patients undergoing treatment for cancer such as improved quality of life and sleep, and reduced treatment-related fatigue. However, individuals receiving treatment for renal cell carcinoma (RCC) often fail to engage in sufficient physical activity. Many cancer survivors experience a decrease in their physical activity after diagnosis2 and the majority of RCC survivors do not meet the recommended guidelines for physical activity.3 Traditional physical activity interventions require significant resources and present substantial barriers for participants (travel, time commitments, etc.). In contrast, mobile technologies enable delivery of interventions with significantly fewer resources. These technologies also facilitate the delivery of just-in-time adaptive interventions (JITAIs) in which intervention support is provided at only at times when an opportunity for positive changes exists.4 The purpose of this support the development of a JITAI in RCC patients. Evaluation of the acceptability and efficacy of three intervention strategies (affective framing, intention planning, goal-setting, and savoring) will determine their inclusion in the JITAI. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Renal Cell

Clinical Trial Details

NCT number	NCT03671304
Study type	Interventional
Source	University of Texas Southwestern Medical Center
Contact
Status	Terminated
Phase	N/A
Start date	November 20, 2020
Completion date	December 22, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02248389` - Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses	Phase 1
Completed	`NCT03900364` - a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy	N/A
Completed	`NCT00158782` - Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients	Phase 1
Completed	`NCT03109015` - Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing	Phase 2
Completed	`NCT00363194` - A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients	Phase 1
Completed	`NCT01012011` - Regulatory Post Marketing Surveillance Study on Nexavar®	N/A
Completed	`NCT00842790` - Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging	N/A
Completed	`NCT00529802` - Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer	Phase 2
Completed	`NCT00338884` - Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer	Phase 2
Completed	`NCT00356460` - Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma	Phase 1
Completed	`NCT00387764` - Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer	Phase 3
Completed	`NCT00095186` - Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma	Phase 2
Completed	`NCT00079612` - Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer	Phase 2
Completed	`NCT00043368` - PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)	Phase 2
Active, not recruiting	`NCT04489771` - A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)	Phase 2
Completed	`NCT00516672` - Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors	Phase 1
Withdrawn	`NCT05104905` - A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma	Phase 1/Phase 2
Terminated	`NCT03685591` - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors	Phase 1
Withdrawn	`NCT03111901` - Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer	Phase 1/Phase 2
Recruiting	`NCT05544929` - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	Phase 1